BusinessAvid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018By Nasdaq OMXMar 5, 2018, 1:05 PM UTC
BusinessAvid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer’s Disease CandidateBy Nasdaq OMXMar 1, 2018, 1:05 PM UTC
BusinessAvid Bioservices Announces Resignation of Chief Financial OfficerBy Nasdaq OMXFeb 26, 2018, 1:05 PM UTC
BusinessAvid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant SciencesBy Nasdaq OMXFeb 21, 2018, 1:05 PM UTC
BusinessAvid Bioservices Announces Pricing of Public Offering of Common StockBy Nasdaq OMXFeb 15, 2018, 10:00 AM UTC
BusinessAvid Bioservices Announces Proposed Offering of Common StockBy Nasdaq OMXFeb 14, 2018, 9:02 PM UTC
BusinessAvid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including BavituximabBy Nasdaq OMXFeb 12, 2018, 1:05 PM UTC
